|Articles|May 1, 2002
- Applied Clinical Trials-05-01-2002
Identifying and Documenting Adverse Events at Clinical Study Sites
Improving adverse event reporting can lead to improved safety profiles and, consequently, fewer drugs pulled from the market.
Advertisement
Articles in this issue
over 24 years ago
Letters to the Editorover 24 years ago
Parents for Orphansover 24 years ago
Fraud, Abuse, and Consentover 24 years ago
Brian Koziolover 24 years ago
A Model-Based Method for Improving Protocol QualityAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
One Clinical: Working Together to Advance Trial Collaboration
2
The CRA of the Future: From Monitoring Activity to Strategic Site Partnership
3
ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma
4
Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV
5